1Department of Oncology, Mayo Clinic, Rochester, Minnesota.
President Donald Trump has issued a number of executive orders (EO) focused on healthcare for people who identify as lesbian, gay, bisexual, transgender, queer, or other sexual or gender minority.
Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...
1i3S—Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal. 2Faculdade de Medicina, Universidade do Porto, Porto, Portugal.
Copyright held by the owner/author(s).
LY3866288, an FGR3-specific inhibitor, led to an objective response in 42% of patients with metastatic urothelial carcinoma in a phase I study. The drug did not induce adverse events more commonly ...
1Department of Radiation Oncology, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas. 2Department of Biochemistry, The University of Texas Southwestern Medical Center at ...
The EZH2 inhibitor mevrometostat, in combination with the androgen receptor signaling inhibitor enzalutamide, improved progression-free survival and objective response rates in patients with ...
1Institute of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China.
Cancer Grand Challenges, Cancer Research UK, London, United Kingdom.
Downregulation of the major histocompatibility complex class I (MHCI) is a mechanism of immune evasion associated with immune-cold tumors, like prostate cancer. Chesner and colleagues conducted a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback